FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

Oncologic Drugs Advisory Committee

Agenda:
The committee will discuss these items:
(1) New Drug Application (NDA) 21-673, proposed trade name CLOLAR (clofarabine) Ilex Products, Inc., proposed indication for the treatment of pediatric patients 1 to 21 years old with refractory or relapsed acute leukemias, and
(2) NDA 21-600, proposed trade name MARQIBO (vincristine sulfate liposome injection) Inex Pharmaceuticals Corp., proposed indication for the treatment of patients with aggressive non-Hodgkin's lymphoma previously treated with at least two combination chemotherapy regimens.

Background material and meeting information will become available no later than one business day before the meeting (Simply select the appropriate committee link).

Procedure:
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 23, 2004. Oral presentations from the public will be scheduled between approximately 10:30 a.m. and 11 a.m., and between approximately 2:30 p.m. and 3 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 23, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Trevelin Prysock at 301-827-7001 at least 7 days in advance of the meeting.

Contact Person:
Johanna M. Clifford, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, Rm. 1093) Rockville, MD 20857, 301-827-7001, Fax: 301-827-6776, e-mail: cliffordj@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512542. Please call the Information Line for up-to-date information on this meeting.